Evercore ISI raised the firm’s price target on Krystal Biotech (KRYS) to $300 from $295 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech price target raised to $378 from $371 at Citi
- Krystal Biotech Earnings Call Highlights Profitable Growth
- Krystal Biotech price target lowered to $311 from $338 at Clear Street
- Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M
- Krystal Biotech reports Q1 EPS $1.83, consensus $1.42